id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-263258-qpzaehg0	Montastruc, François	Hepatic disorders with the use of remdesivir for coronavirus 2019 (COVID-19)	2020-07-25		.txt	text/plain	870	60	46	3 In cohort studies of patients hospitalized for severe COVID-19 who were treated with compassionate-use remdesivir, hepatic enzyme elevated were the most frequent adverse drug reaction reported. 4, 5 In the first randomized, double-blind, placebo-controlled clinical trial assessing the effect of intravenous remdesivir in adults admitted to hospital with severe COVID-19 (n= 237) a higher proportion of remdesivir recipients than placebo recipients had dosing prematurely stopped by the investigators because of adverse events including aminotransferase or bilirubin increases (3 versus 0). Here, we performed a pharmacovigilance analysis of VigiBase, the World Health Organization's individual case safety reports database, to describe hepatic impairment reports with remdesivir. Disproportionality analysis was performed to assess a potential increased risk of reporting hepatic disorders with remdesivir compared to drugs prescribed in COVID-19 patients. Compared with hydroxychloroquine, lopinavir/ritonavir or tocilizumab, the use of remdesivir was associated with an increased risk of reporting hepatic disorders (ROR 1.94; 95% 7 Abbreviations: CI, confidence interval; COVID-19, coronavirus disease 2019 ; ROR, reporting odds ratio.	./cache/cord-263258-qpzaehg0.txt	./txt/cord-263258-qpzaehg0.txt